Vimarsana
Biggest News Aggregation in the World

Page 3 - Arnaud Delepine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnaud Delepine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnaud Delepine Today - Breaking & Trending Today

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review - Vimarsana News

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat ...

Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine - Vimarsana News

Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine

Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the... | May 21, 2023

Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program - Vimarsana News

Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program

TARRYTOWN, N.Y. and PARIS, Feb. 18, 2022 /PRNewswire/ -- In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistic...

FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis - Vimarsana News

FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

TARRYTOWN, N.Y. and PARIS, Feb. 10, 2022 /PRNewswire/ --If approved, Dupixent will be the first biologic medicine available in the U.S. to treat u...